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RESEARCH
Cysteamine broadly improves the 
anti-plasmodial activity of artemisinins 
against murine blood stage and cerebral 
malaria
Neda Moradin1, Sabrina Torre2, Susan Gauthier1, Mifong Tam3, Jalal Hawari4, Kirsten Vandercruyssen5, 
Bart De Spiegeleer5, Anny Fortin1, Mary M. Stevenson3 and Philippe Gros1*
Abstract 
Background: The potential emergence and spread of resistance to artemisinins in the Plasmodium falciparum 
malaria parasite constitutes a major global health threat. Hence, improving the eﬃcacy of artemisinins and of 
artemisinin-based combination therapy (ACT) represents a major short-term goal in the global ﬁght against malaria. 
Mice defective in the enzyme pantetheinase (Vnn3) show increased susceptibility to blood-stage malaria (increased 
parasitaemia, reduced survival), and supplementation of Vnn3 mutants with the reaction product of pantetheinase, 
cysteamine, corrects in part the malaria-susceptibility phenotype of the mutants. Cysteamine (Cys) is a small, naturally 
occurring amino-thiol that has very low toxicity in vivo and is approved for clinical use in the life-long treatment of 
the kidney disorder nephropathic cystinosis.
Methods: The ability of Cys to improve the anti-plasmodial activity of diﬀerent clinically used artemisinins was tested. 
The eﬀect of diﬀerent CYS/ART combinations on malarial phenotypes (parasite blood-stage replication, overall and 
survival from lethal infection) was assessed in a series of in vivo experiments using Plasmodium strains that induce 
either blood-stage (Plasmodium chabaudi AS) or cerebral disease (Plasmodium berghei ANKA). This was also evaluated 
in an ex vivo experimental protocol that directly assesses the eﬀect of such drug combinations on the viability of Plas-
modium parasites, as measured by the ability of tested parasites to induce a productive infection in vivo in otherwise 
naïve animals.
Results: Cys is found to potentiate the anti-plasmodial activity of artesunate, artemether, and arteether, towards the 
blood-stage malaria parasite P. chabaudi AS. Ex vivo experiments, indicate that potentiation of the anti-plasmodial 
activity of artemisinins by Cys is direct and does not require the presence of host factors. In addition, potentiation 
occurs at sub-optimal concentrations of artemisinins and Cys that on their own have little or no eﬀect on parasite 
growth. Cys also dramatically enhances the eﬃcacy and protective eﬀect of artemisinins against cerebral malaria 
induced by infection with the P. berghei ANKA parasite.
Conclusion: These ﬁndings indicate that inclusion of Cys in current formulations of ACT, or its use as adjunct therapy 
could improve the anti-plasmodial activity of artemisinin, decrease mortality in cerebral malaria patients, and prevent 
or delay the development and spread of artemisinin resistance.
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Background
Malaria is a severe threat to global health with an esti-
mated 300–500 million cases annually and  >1 million 
deaths. In endemic areas of Africa, malaria accounts for 
25 % of paediatric deaths [1, 2]. Plasmodium falciparum 
is by far the deadliest of the four human malarial spe-
cies (P. falciparum, Plasmodium malariae, Plasmodium 
ovale, and Plasmodium vivax). The clinical symptoms 
of malaria occur at the blood stage when parasites rap-
idly replicate and lyse red blood cells (RBCs) leading to 
anemia and high fever. In addition, parasitized RBCs can 
become trapped and cause lesions in brain capillaries 
resulting in cerebral malaria (CM), the most lethal form 
of the disease [3].
Treatment of clinical malaria relies on a handful of 
drugs, the most potent being artemisinin derivatives 
(called the artemisinins or ADs), a group of structur-
ally related molecules that includes artesunate (ART), 
artemether (ARTM) and arteether (ARTE) [4–6]. To 
avoid appearance and spread of artemisinin resistance 
in P. falciparum, the World Health Organization (WHO) 
has strongly discouraged use of artemisinins as a sin-
gle agent, and artemisinin monotherapy is only recom-
mended for lethal cerebral malaria [3]. Rather, and for all 
other forms of clinical disease, artemisinins are adminis-
tered in combination (artemisinin combination therapy; 
ACT) with other, long acting, anti-malarial drugs that 
include meﬂoquine, lumefantrine, amodiaquine, pipe-
raquine and sulfadoxine/pyrimethamine [4, 5]. Because 
no other drugs as potent as artemisinins are available, 
the potential emergence of artemisinin resistance at 
Thai/Cambodia border and its spread to other areas has 
caused signiﬁcant concerns [7–11], including the failure 
of front line ACT due to secondary partner drug resist-
ance. Although the mechanisms of artemisinin resistance 
in Plasmodium are being characterized [12–16], novel 
adapted treatment options based on this knowledge are 
years away. Hence, improving the eﬃcacy of artemisinins 
and of ACT represents a major short-term goal in treat-
ing and preventing the spread of artemisinin resistance 
in the malaria parasite. Likewise, increasing eﬀectiveness 
of adjunct treatment to artemisinin monotherapy may 
improve the outcome of cerebral malaria, the most severe 
and most diﬃcult to treat complication of malaria.
Studies in human populations from areas of endemic 
disease have long established the critical role of genetic 
factors in susceptibility and protection against malaria 
[17, 18]. Examples include the protective eﬀect of het-
erozygosity for loss of function variants at erythro-
cyte-speciﬁc proteins such as haemoglobin (sickle cell 
anaemia, thalassaemias), glucose 6-phosphate dehy-
drogenase, anion exchanger 1 (SLC4A1), Duﬀy anti-
gen (DARC), ABO blood group variants and several 
others [17, 19]. Likewise, studies in mouse models of 
blood stage malaria (Plasmodium chabaudi AS), and of 
cerebral malaria (Plasmodium berghei ANKA) have also 
established a strong genetic control of resistance and 
susceptibility to malaria, and the molecular basis has 
been characterized in several instances [20], providing 
potentially useful entry points for discovery of novel anti-
malarial drugs or other treatment modalities [21, 22].
In a mouse model of infection with P. chabaudi, it was 
reported that a loss of function in the enzyme panteth-
einase (Vnn1/Vnn3) in mouse strain AcB61 causes sus-
ceptibility to blood-stage malaria [23]. The Vnn1/Vnn3 
pantetheinases are enzymes that hydrolyze pantetheine 
to pantothenic acid (vitamin B5) and Cysteamine (Cys). 
Furthermore, Cys displays modest but signiﬁcant anti-
malaria activity, and Cys treatment can signiﬁcantly 
improve the response of mice to blood stage infection 
with P. chabaudi (reduced parasitaemia, increased sur-
vival), when given either as a prophylactic (naïve ani-
mals) or as a therapeutic (infected animals) regimen [24]. 
Ex  vivo, Cys inhibits the degradation of hemoglobin by 
Plasmodium parasites in erythrocytes [24].
Cys is a small, naturally occurring amino thiol that 
has very low toxicity in  vivo. Importantly, diﬀerent Cys 
formulations are approved for life-long treatment of 
nephropathic cystinosis (NC), a kidney disorder caused 
by mutations in the lysosomal cystine carrier cystino-
sin [25]. It was reported that Cys dosing regimens that 
display pharmacokinetic proﬁles similar to those meas-
ured in humans taking oral Cys for the treatment of NC, 
reduce replication of the malaria parasite in  vivo, and 
reduce lethality from infection [26]. In the present study, 
the potential of Cys to increase the anti-plasmodial activ-
ity of diﬀerent artemisinins towards the murine Plas-
modium parasites P. chabaudi AS (blood-stage), and P. 
berghei ANKA (cerebral malaria) was investigated. Cys 
is shown to potentiate the activity of several artemisinins 
currently in clinical use in ACT, including ART, ARTE, 
and ARTM, against the blood stage of the infection by P. 
chabaudi in mice. Cys also causes dramatic enhancement 
of artemisinin eﬃcacy and protective eﬀect against cer-
ebral malaria induced in the mouse by infection with the 
ANKA strain of P. berghei.
Methods
Mice and parasites
Eight to twelve weeks old female A/J mice were pur-
chased from the Jackson Laboratories (Bar Harbor, ME, 
USA) and were housed at McGill University Animal 
Care Center according to the guidelines of the Canadian 
Council on Animal Care. Mice experimentation pro-
tocol was approved by the McGill Facility Animal Care 
Committee (P. Gros, Principal Investigator; protocol 
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number: 5287), and include procedures to minimize dis-
tress and improve welfare. An isolate of P. chabaudi AS 
was provided by Dr. Mary M. Stevenson (McGill Uni-
versity Health Center Research Institute, Montreal), 
and was maintained by weekly passage in A/J mice for 
a maximum of four consecutive passages, as previously 
described [27]. Plasmodium berghei ANKA parasites 
were initially obtained from the Malaria Reference and 
Research Reagent Resource Center (MR4); P. berghei 
was passaged in C57BL/6J (B6) mice for a maximum of 
three consecutive passages. In passage mice, blood par-
asitaemia was monitored daily, and the percentage of 
parasitized red blood cells (pRBCs) was determined on 
thin blood smears stained with Dif-Quik (Dade Behring, 
Newark, DE, USA), as described [28]. Infected blood was 
diluted in pyrogen-free saline for infection of experimen-
tal animals and also for preparation of cryo-preserved 
stocks for long-term storage.
Drugs and drug treatments
Cysteamine hydrochloride (Cys) and N-acetyl cysteine 
(NAC) (Sigma, Burlington ON, Canada) were prepared 
fresh in PBS. Artesunate and artemether were generously 
provided by Dafra Pharma International (Turnhout, Bel-
gium). Artesunate was prepared fresh as a 1 mg/mL stock 
in 5 % sodium bicarbonate solution which was diluted in 
PBS immediately before use. Artemether (Artesiane™) 
prepared from fractionated coconut oil stock (20  mg/
mL, injectable) was diluted in sesame oil to desired con-
centration. Beta-Arteether (Artecef™, Artemotil; 50  mg/
mL injectable in sesame oil) was diluted in sesame oil to 
desired concentration. Beta-Arteether was generously 
provided by Artecef BV (Zeewolde, The Netherlands). 
Drugs were administered via intraperitoneal (i.p) injection 
and according to a four-days treatment schedule. Mice 
were weighed prior to treatment to determine appropriate 
doses and injection volumes ranged from 100–400 μL per 
mouse. In the case of animals treated with two drugs, Cys 
was administered ﬁrst, followed by artemisinin derivatives 
15  min later on alternate sides of the mouse abdomen. 
Untreated control animals were injected with PBS alone.
Infections
For in vivo infections, mice were infected i.v. (0.2 mL) with 
107 P. chabaudi pRBCs into the tail vein, and monitored 
under BSL2 containment conditions. One hour post-
infection, mice received either PBS or diﬀerent drugs or 
drug combinations (i.p), and this treatment was repeated 
at 24, 48, and 72  h post-infection. At day 4 and 5 post-
infection, blood was sampled, and blood parasitaemia 
was determined (between 4–10 ﬁelds of 100 erythrocytes 
were counted per mouse, and results are expressed as 
percentage of parasitized erythrocytes). For experiments 
involving ex vivo drug exposure followed by in vivo infec-
tions, parasitized erythrocytes were exposed to certain 
compounds for 1  h at 37  °C. Treated pRBCs were then 
rinsed free of drug, and resuspended in drug-free PBS (at 
1 ×  106 pRBC/mL), and were then used to infect naïve 
mice (1 × 105 pRBC). The ability of the treated parasites 
to induce a productive infection was monitored by meas-
uring blood parasitaemia daily, and by monitoring appear-
ance and progression of lethal and irreversible symptoms 
of cerebral malaria, as we described [29].
Pharmacokinetic studies of artemisinin in vivo
Mice were injected with Cys (140 mg/kg, 0.2 mL, i.p.) in 
the lower left abdomen, and exactly 15  min later, ART 
(0.5  mg/kg, 0.2  mL, i.p.) was injected in the lower right 
abdomen. At 5, 10, and 20  min, mice were euthanized 
and bled by cardiac puncture and blood was collected in 
EDTA-containing tubes to isolate plasma. Plasma samples 
showing hemolysis were not used for ART determination 
as haemolysis interfered with ART measurement. Control 
plasma from untreated mice was also included as a pla-
cebo for spiked calibration references covering a range 
between 5 and 2000 ng/mL for ART as well as DHA, and 
QC samples (10 and 100 ng/mL). The method consisted 
of a sample preparation step, followed by UPLC with MS 
(MRM-mode) detection. Brieﬂy, a protecting solution 
consisting of potassium oxalate and sodium ﬂuoride was 
added to ice-cold mouse plasma, followed by the addition 
of the ART-d3 and DHA-d3 internal standard solutions. 
After mixing, the diluted plasma samples were loaded 
on preconditioned μ-HLB-SPE wells, which are washed 
with water followed by 5 % acetonitrile in water. Elution 
of the compounds was done with a methanol–acetonitrile 
mixture, and diluted with water before injection in the 
UPLC system, consisting of an Acquity BEH shield RP18 
column with a mobile phase consisting of water-acetoni-
trile-formic acid (50/50/0.1) in isocratic mode. The MRM 
transitions used for quantiﬁcation were m/z 283→265, 
resp 286→268, for ART and its internal standard, and 
m/z 323→240, resp 326→243, for DHA and its internal 
standard. The method was validated and found to comply 
for linearity, selectivity, recovery, accuracy and precision.
Evans blue dye extravasation
Plasmodium berghei parasites were subjected to ex vivo 
drug exposure followed by intravenous injection in B6 
mice. At day 6 post-infection, mice were injected intra-
venously with 0.2  mL 1  % Evans blue dye prepared in 
sterile PBS. One hour later, mice were exsanguinated 
and perfused with PBS-containing 2 mM EDTA. Brains 
were excised, imaged, and incubated with 1 mL of dime-
thyl formamide for 48 h to extract Evan’s blue dye from 
the tissues. Optical density was measured at 610 nm, and 
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measurements were converted into μg of dye extrava-
sated per gram of tissue.
Leukocyte infiltration in the brain
Six days post-infection, mice were exsanguinated and 
perfused as above; brains were harvested and homog-
enized in RPMI media-containing 0.5  mg/mL colla-
genase (Gibco LifeTechnologies), 0.01  mg/mL DNAse 
I (Roche) and 2 mM EDTA. Inﬁltrating cells were sepa-
rated on a 33.3  % Percoll solution. Cells were stained 
for ﬂow cytometry analyses with the following; Zombie 
Aqua Dye-V500 (BioLegend), anti-CD45-APC-eFluor780 
(clone 30-F11, eBioscience), anti-CD4-PerCP Cyanine5.5 
(clone RM4-5, eBioscience), anti-CD8alpha-PE (clone 
53-6.7, eBioscience), anti-TCRbeta-FITC (clone H57-597, 
eBioscience), anti-CD19-BV421 (clone 6D5, BioLegend), 
F4/80-eFluor450 (clone BM8, eBioscience), anti-CD11b-
APC (clone M1/70, eBioscience), anti-CD11c-PerCP 
Cyanine5.5 (clone N418, eBioscience), anti-Ly6C-PE 
(clone HK1.4, eBioscience), and anti-Ly6G-FITC (clone 
1A8, BioLegend). Leukocytes were gated as CD45hi cells.
Statistical tests
Groups with normally distributed data points were com-
pared using parametric unpaired t tests, while groups 
with non-Gaussian distributions were compared using 
non-parametric Mann–Whitney tests. Survival diﬀer-
ences were analysed using the Log-Rank test. Standard 
error of percent inhibition was calculated from individ-
ual mice compared to the mean parasitaemia level of the 
control group.
Results
Cys enhances the anti-plasmodial activity of different 
artemisinin molecules against blood stage malaria in vivo 
(P. chabaudi)
The capacity of Cys to potentiate the anti-plasmodial 
activity of diﬀerent ADs present in clinically-used ACT, 
including ART, ARTM, and β-ARTE (Fig. 1a) was inves-
tigated. ADs were given at sub-optimal concentrations 
(doses that have little eﬀect on parasitaemia and survival 
on their own) to distinguish between the lack of an eﬀect 
and possible additive or synergistic eﬀects of Cys on the 
ADs, as previously described [26]. Synergy is deﬁned as a 
total activity of the two compounds given together being 
greater than the sum of the independent activities of the 
two compounds given alone. The eﬀect of Cys on ADs 
anti-plasmodial activity was determined using a stand-
ardized four-day test using blood parasitaemia as a quan-
titative measure of anti-plasmodial activity (Fig.  1b). In 
these experiments, mice were infected with P. chabaudi 
(107 pRBC through i.v. route), and 1 h later, they received 
either PBS, Cys (140 mg/kg) and/or sub-optimal doses of 
ADs (between 0.05 or 0.5 mg/kg) given i.p. Parasitaemia 
levels were subsequently measured on day 4 and survival 
time was monitored.
For ART (Fig.  2a), sub-optimal dosing of 0.2  mg/kg 
(ART0.2) caused a modest ~10 % reduction of parasi-
taemia compared to untreated controls, while a higher 
dose (0.5 mg/kg; ART0.5) produced ~70 % inhibition; 
Addition of Cys to these two regimens resulted in fur-
ther strong reduction of parasitaemia, with either a 
synergistic (ART0.2/Cys) or additive effect (ART0.5/
Cys) (Fig.  2a). In addition, mice receiving both ART/
Cys showed fewer symptoms of disease, and had a sig-
nificant increase in survival time: from day six post-
infection for control mice (PBS) and mice receiving 
either Cys alone or ART low dose (ART0.2), to day 7 
for those receiving ART high dose (ART0.5) and the 
ART0.2/Cys combination, to day 10 for mice receiv-
ing ART0.5/Cys (Additional file  1A). For ARTM, the 
strongest effect on parasite replication was seen for 
the ARTM (0.2 mg/kg)/Cys combination (98 %), com-
pared to Cys (33  %) or ARTM (29  %) alone (Fig.  2b). 
The ARTM (0.2  mg/kg)/Cys combination produced a 
synergistic effect and completely blocked parasite rep-
lication (<1  % parasitaemia at day 4), and completely 
protected against lethality with 100  % survival of 
mice in this group compared to mice receiving either 
PBS, Cys or ARTM alone (Additional file  1B). Dose–
response studies (Fig.  2c) showed that the potenti-
ating effect of Cys was dose-dependent, and that a 
minimum dosing of 60  mg/kg was required for clear 
potentiation of ARTM effect on blood parasitaemia. 
Maximum potentiation was seen at 80 and 100 mg/kg 
Cys (Fig. 2c), with animals in these two groups surviv-
ing past day 7 (Additional file  1C). Cys was also able 
to potentiate the anti-plasmodial activity of ARTE; 
while single dosing of Cys (140 mg/kg) or ARTE (0.05; 
0.2  mg/kg) caused a maximum reduction of  ~20  % in 
blood parasitaemia, the addition of Cys to high dose 
ARTE caused a nearly ~80 % reduction in parasitaemia 
(Fig.  2d), and increased survival to day 8 (Additional 
file 1D) compared to PBS-treated controls (100 % mor-
tality by day 5). Similar to the effect of Cys on ARTM 
activity, potentiation of ARTE was dose-dependent, 
with optimal effects seen at a dose of 100  mg/kg Cys 
(Additional file 2).
Taken together, these results (representative of three 
independent experiments) indicate that Cys can poten-
tiate the anti-plasmodial activity of chemically distinct 
artemisinin molecules in vivo, reducing blood stage para-
site replication and increasing survival following acute 
infection.
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Cys enhances the anti-plasmodial activity of artemisinin 
against blood stage malaria ex vivo (P. chabaudi)
A series of experiments were conducted to determine 
whether the Cys potentiation of ADs anti-plasmodial 
activity noted against P. chabaudi in  vivo is due to (a) 
increased drug induced anti-plasmodial activity, or (b) 
indirect static or cidal mechanisms involving the parasite 
replication niche (RBC) and/or host innate defenses. For 
this, P. chabaudi pRBCs were exposed to drugs in vitro, 
and the eﬀect of this exposure on the ability of the treated 
preparations to induce infection in a naïve host in  vivo 
was tested (Fig. 1c). Plasmodium chabaudi pRBCs were 
exposed for 1 h at 37 °C to either PBS, Cys (50 μM), ART 
(5, 10  μM) or both, which was subsequently washed 
oﬀ; The equivalent of 1 ×  105 pRBCs (calculated prior 
to drug exposure) was then injected into mice with-
out any additional exposure to drugs in  vivo, and para-
site replication was followed over time (Fig. 3a). Results 
show that although a 1  h treatment with Cys alone or 
with ART alone (at both doses) had minimal eﬀect on 
time of appearance and extent of blood stage replica-
tion, parasites treated with Cys (50  μM)/ART(10  μM) 
Fig. 1 Experimental framework for testing anti-plasmodial activity of drug combinations. a Molecular structure of drugs used in the study. b Two 
types of infection protocols were used. For the in vivo/in vivo assay, mice were infected through the i.v. route with 107 Plasmodium parasitized red 
blood cells (pRBCs). One hour later, drugs were administered through the i.p. route, parasitaemia was monitored on thin blood smears over time, 
and mortality was recorded. c For the ex vivo/in vivo assay, Plasmodium parasitized red blood cells were exposed for 1 h at 37 °C to diﬀerent drug 
combinations. They were then washed free of drugs, counted and naïve mice were infected with 105 treated pRBCs. Parasitaemia was monitored on 
thin blood smears over time, and mortality is recorded
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combination showed (a) considerable delay in onset of 
parasitaemia, (b) striking  >90  % inhibition of parasite 
replication measured at day 9 and day 10, compared to 
PBS treated controls, and (c) signiﬁcant survival (80 %) to 
infection compared to all other treatment groups which 
succumbed to infection by day 10 (Fig. 3b). These results 
indicate that Cys can strongly potentiate the anti-plas-
modial activity of ART in a single 1 h exposure of pRBCs, 
signiﬁcantly reducing parasite viability. The Cys enhance-
ment of anti-parasitic activity is detected ex vivo, in the 
absence of the host immune system, strongly pointing at 
a direct enhancement of ART potency.
Specificity of the Cys effect
Cys is a naturally occurring amino-thiol that contains 
a thiol group which confers anti-oxidant properties 
(Fig.  1a). To determine whether the potentiating eﬀect 
of Cys on artemisinin anti-plasmodial activity is speciﬁc, 
Cys was compared to another closely related aminothiol 
with similar anti-oxidant properties, N-acetyl-Cysteine 
(NAC; Fig.  1a). Mice were infected by 107 P. chabaudi 
pRBCs, and the infected mice were treated with either 
PBS, ARTM (0.2  mg/kg), Cys (MW 113) or NAC (MW 
163) used at the same dose (70 mg/kg) alone or in com-
binations with ARTM (Fig.  4). The eﬀect of drugs on 
blood stage replication of P. chabaudi was measured on 
day four post-infection (Fig. 4a). Results show that at the 
70  mg/kg dose used, neither Cys alone nor NAC alone 
had a signiﬁcant eﬀect on P. chabaudi replication, and at 
the sub-optimal dosing of 0.2  mg/kg tested, ARTM had 
only a moderate eﬀect on blood parasitaemia on day 4. 
As expected, the Cys/ARTM combination showed poten-
tiation and caused a >90 % inhibition of parasite replica-
tion. By contrast, adding NAC to ARTM did not improve 
the anti-plasmodial eﬀect of ARTM (~40  % inhibition). 
Cys/ARTM also improved survival to infection (up to 
Fig. 2 Potentiation of anti-plasmodial activity of artemisinin derivatives by Cys in Plasmodium chabaudi AS blood-stage infection (in vivo assays). 
Groups of A/J mice (minimum of 5 mice per group) were infected with P. chabaudi pRBCs, and were treated with diﬀerent drug regimens at the 
indicated doses (in mg/kg). Cys dose was ﬁxed at 140 mg/kg in panels a, b, and d, and at variable doses (20, 40, 60, 80, 100 mg/kg) in panel c. 
Artemisinin derivatives tested were ART (a), ARTM (b, c), and ARTE (d). The intensity of infection (blood parasitaemia) was measured at day 5 post-
infection and is shown as whisker plots (interquartile ranges; mean, with minimum to maximum). The inhibitory activity of diﬀerent drug treatments 
is shown as a fraction (% inhibition) of parasitaemia detected in control mice treated with PBS. Statistical signiﬁcance was calculated by unpaired 
student t test, *p < 0.05. The data is representative of three independent experiments
Fig. 3 Potentiation of anti-plasmodial activity of ART by Cys in Plasmodium chabaudi blood-stage infection (ex vivo/in vivo assay). P. chabaudi para-
sitized red blood cells (pRBC) were exposed to diﬀerent drug combinations in vitro for 1-h at 37 °C, washed free of drugs and then used to infect 
naïve mice. Groups of A/J mice (minimum of 5 mice per group) were infected with 105 drug-treated P. chabaudi pRBCs, and infected mice were 
monitored for blood parasitaemia (a) at the indicated times post-infection (days 7–10). Drug concentrations are in micromolar (μM). Mortality was 
recorded (b). Data is representative of three independent experiments and it is expressed as mean ± SD for each group (*p < 0.05)
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8 days), compared to mice from all other groups and that 
succumbed from infection between day 5 and 6 (Fig. 4b). 
Therefore, potentiation by Cys is speciﬁc and cannot be 
achieved with NAC.
Cys enhances the anti-plasmodial activity of artemisinin 
against cerebral malaria (P. berghei)
Experimental cerebral malaria (ECM) can be induced 
in mice by infection with P. berghei. In this model, clini-
cal symptoms occur at relatively low levels of blood 
parasitaemia (<20  %), and are not driven by haemolytic 
anaemia, but rather, by host pathological inﬂammatory 
reactions. Indeed, brain endothelial cells activated by 
pRBCs produce cytokines and chemotactic factors that 
recruit neutrophils and activated T lymphocytes. Release 
of cytotoxic molecules by inﬂammatory leukocytes leads 
to loss of integrity of the blood–brain barrier, micro-
thrombosis, hypoxia of the brain parenchyma, leading 
to neurological symptoms including seizures and coma, 
and ultimately death [21, 22]. To determine whether Cys 
could be of therapeutic beneﬁt against cerebral malaria, 
its capacity to potentiate the anti-plasmodial activity of 
ART against P. berghei was tested using the ex vivo expo-
sure: in vivo infection model (Fig. 1c). Brieﬂy, P. berghei-
parasitized RBCs were exposed to diﬀerent Cys/ADs 
combinations for one hour at 37 °C, and 105 of the treated 
pRBC were injected into naïve mice. These were then 
followed for daily blood parasitaemia, for appearance 
of clinical symptoms, and survival was also recorded. 
Treatment of pRBCs in  vitro with combinations of Cys 
(50 μM) plus ART (5, 10 μM) caused a signiﬁcant delay 
in the onset of parasitaemia, and on the extent of parasite 
replication compared to pRBCs treated with either PBS, 
or with either Cys or ART alone (Fig. 5a). There was also 
a dramatic increase in the survival of mice infected with 
pRBCs treated with either Cys/ART combinations (80–
100  % survival beyond day 13) (Fig.  5b). The enhanced 
anti-parasitic activity of the Cys/ART combination over 
either drug alone used to treat pRBCs in  vitro was still 
evident when dosing as low as 25 μM Cys (Fig. 5c, d) or 
even 15  μM (Fig.  5e) were used. Together, these results 
(representative of 3 independent experiments) show that 
(a) Cys alone has signiﬁcant activity against P. berghei; (b) 
Cys can strongly potentiate the anti-plasmodial activity 
of ART in the experimental cerebral malaria model; and 
(c) potentiation by Cys occurs at doses that are below 
those currently approved for life-long clinical treatment 
of cystinosis in humans.
The integrity of the blood brain barrier (BBB) of mice 
infected with P. berghei parasites (pRBCs) treated ex vivo 
with either PBS, Cys, ART or ART/Cys was also investi-
gated, using an Evans blue extravasation assay [30, 31]. 
For this, mice at day six post-infection are injected with 
Evans blue, and the dye is allowed to circulate for 1  h 
prior to sacriﬁce. Brains of the mice were harvested, and 
the Evans blue dye was quantiﬁed (Fig. 6a). Mice infected 
with Cys/ART-treated P. berghei displayed preserved 
BBB integrity with signiﬁcant dye exclusion, and this was 
clearly distinct from mice infected with P. berghei pRBCs 
treated with either PBS, Cys, or ART alone which dem-
onstrated compromised BBB function (Fig. 6a). In paral-
lel experiments, P. berghei-infected mice were sacriﬁced 
at day 6 post-infection, exsanguinated, and perfused 
with PBS; isolated cells from the brain were analysed 
Fig. 4 Speciﬁcity of Cys versus N-acetyl-Cysteine in potentiation of ARTM in Plasmodium chabaudi blood-stage infection. Mice (minimum of 5 mice 
per group) were infected by 107 P. chabaudi pRBC through the i.v. route, and blood parasitaemia was monitored (a), and mortality was recorded 
(b), as described in legend of Fig. 2. The results show that at equivalent concentrations, Cys (70 mg/kg) can strongly potentiate the anti-plasmodial 
activity of ARTM (0.2 mg/kg), while NAC (70 mg/kg) has no eﬀect. Statistical signiﬁcance was calculated by unpaired student t test, *p < 0.05. Data 
are from one of two independent experiments that produced similar results
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by ﬂuorescence activated cell sorting (FACS) for the 
presence and number of inﬁltrating inﬂammatory cells 
(Fig. 6b, c). Mice infected with P. berghei parasites treated 
with Cys/ART combination showed reduced inﬁltra-
tion of total CD45hi leukocytes, including macrophages 
(CD11b+F4/80+), neutrophils (CD11b+Ly6G+), CD19+ 
B lymphocytes, and CD4+ and CD8+ T lymphocytes 
(TCRβ+) (Fig.  6b, c). Taken together, these results indi-
cate that improved clinical symptoms and overall sur-
vival in mice infected with P. berghei parasites treated 
with Cys/ART is associated with improved BBB function, 
reduced inﬁltration of pro-inﬂammatory myeloid and 
lymphoid cells, and absence of cerebral pathology.
Discussion
In previous reports from our group, Cys was shown to 
have low but signiﬁcant anti-plasmodial activity, and 
could also potentiate ART in an in vivo model of blood-
stage malaria with P. chabaudi [27]. Building on these ini-
tial results, the current studies demonstrate that (a) the 
eﬀect of Cys is broad, as it is found to potentiate the anti-
plasmodial activity of structurally distinct artemisinin 
drugs in current clinical use in ACTs, (b) Cys increases 
the anti-plasmoidal activity of ART against both blood 
stage and cerebral forms of malaria, and (c) the Cys eﬀect 
is direct, does not require host factors, and can be dem-
onstrated on isolated Plasmodium-infected erythrocytes.
Fig. 5 Potentiation of anti-plasmodial activity of ART by Cys in Plasmodium berghei cerebral malaria (ex vivo/in vivo assay). P. berghei pRBCs were 
exposed to diﬀerent drug combinations (indicated in micromolar, μM) in vitro for 1 h at 37 °C (see Fig. 1). They were then washed free of drugs and 
used to infect naïve mice. Groups of C57BL/6J (B6) mice (minimum of 5 mice per group) were infected with 105 drug-treated P. berghei ANKA-pRBCs, 
and monitored for blood parasitaemia (a, c, e) at the indicated times post-infection, and mortality was recorded (b, d). The potentiation of ART by 
decreasing concentrations of Cys, 50 micromolar (a, b), 25 micromolar (c, d), 15 and 5 micromolar (e) was tested. Mortality on panels a, c, e is indi-
cated by a cross. Data is expressed as mean ± SD for each group (*p < 0.05). The data is representative of three independent experiments
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Cys can strongly potentiate the anti-plasmodial activ-
ity of the artemisinin derivatives ART, ARTM and ARTE. 
Artemisinin is itself a poor water-soluble and unstable 
sesquiterpene lactone that is not generally used clinically. 
ART, ARTM, ARTE, and dehydroartemisinin (DHA) are 
structural analogs of artemisinin that are in clinical use in 
current ACTs, including DHA-piperaquine (Artequick), 
ART-meﬂoquine, ART-amodiaquine, ART-sulfadoxine-
pyrimethamine, ART-sulfamethoxypyrazine-pyrimeth-
amine, and ARTM-lumefantrine [4, 5, 32]. In a standard 
four-day test in mice, Cys can strongly potentiate the anti-
plasmodial activity of ART, ARTM, and ARTE against the 
blood stage parasite P. chabaudi, as determined by strong 
reduction of blood parasitaemia, and increased survival 
from acute infection. The observed eﬀect of Cys on ART, 
ARTM, and ARTE suggests a potentiation mechanism 
that is independent of side chains substitutions of the 
main sesquiterpene lactone. Importantly, these results 
suggest that inclusion of Cys to current artemisinin-
based anti-plasmodial drug formulations could improve 
eﬃcacy of several ACTs. Furthermore, Cys potentiation 
of the anti-plasmodial activity of ART is observed for 
Plasmodium parasites that cause diﬀerent pathologies, 
namely haemolytic anaemia associated with blood-stage 
replication of P. chabaudi AS, but also cerebral malaria 
associated with neuroinﬂammation caused by trapping 
of P. berghei parasitized erythrocytes at the blood brain 
barrier [23, 24, 26]. Hence, it is tempting to speculate 
Fig. 6 Reduced cerebral pathogenesis in mice infected with Plasmodium berghei treated with Cys/ART combination (ex vivo/in vivo assay). a Evans 
blue extravasation was used to assess integrity of the blood–brain barrier (BBB) of mice infected with P. berghei pRBCs treated ex vivo with either 
PBS, cysteamine (Cys) or artesunate (ART) alone, or in combination (ART/Cys) [see legend to Fig. 4]. Six days post-infection, mice were injected 
with Evans blue dye, the brains were harvested and photographed, and dye accumulation was quantiﬁed. Data is expressed as mean ± SD for each 
group (*p < 0.05). b, c Six days following P. berghei infection, inﬁltrating leukocytes were isolated by centrifugation on a 33.3 % Percoll gradient 
from brain homogenates and were analysed by FACS. b Representative FACS plots of cellular inﬁltration in the brain indicate reduced inﬁltration 
of CD45hi leukocytes, CD45+CD4+ T cells, CD45+CD8+ T cells, TCRb−CD19+ B cells, F4/80+CD11b+ macrophages, and Ly6G+CD11b+ neutrophils 
in brains of mice that received ex vivo-exposed ART/Cys P. berghei parasites. c Data are expressed as the total number of viable cells in the brain, 
expressed as mean ± SD for each group (*p < 0.05)
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that Cys may prove beneﬁcial against diﬀerent forms of 
malaria in humans.
What is the mechanism by which Cys potentiates the 
anti-plasmodial activity of artemisinins? This question 
remains unanswered. However, the present study shows 
that Cys potentiation may aﬀect several aspects of the 
pathophysiology of Plasmodium infection. First and fore-
most, in vitro studies show that Cys can directly enhance 
the anti-plasmodial activity of artemisinins (in a 1 h assay), 
and without involvement of host-based mechanisms: 
Indeed, erythrocytes parasitized with diﬀerent Plasmo-
dium species (P. chabaudi, P. berghei) and exposed to the 
Cys/artemisinin combinations show signiﬁcantly reduced 
capacity to induce a productive infection in naïve hosts 
(reduced blood parasitaemia and clinical symptoms, and 
increased survival). The observation that in this 1 h expo-
sure assay, Cys can potentiate artemisinin activity, reduc-
ing infectivity and improving clinical endpoints (lethality) 
of Plasmodium parasite infections that involve diﬀerent 
pathogenesis and causes of death (severe anaemia, enceph-
alitis) support a direct increase in anti-parasitic property 
of the artemisinin/Cys combination. This proposal is sup-
ported by studies showing that Cys has modest but signiﬁ-
cant anti-plasmodial properties in vivo [24, 26].
In addition, Cys may have additional eﬀects in vivo that 
may further enhance the anti-plasmodial properties of 
artemisinins. Indeed, in a parallel set of experiments, Cys 
pre-treatment was observed to aﬀect pharmacokinet-
ics of plasma ART, seemingly delaying the time of peak 
plasma concentration, from 5  min in controls (no Cys) 
to 10  min in Cys-treated mice (Additional ﬁle  3A, B), 
although there did not seem to be an eﬀect on bioavail-
ability (area under the curve; AUC). Cys also appeared 
to have an eﬀect on the bio-transformation of ART to its 
biologically active species, dehydroartemisinin (DHA) 
[33, 34]. Results in Additional ﬁle  3C, D show that lev-
els of plasma DHA were signiﬁcantly higher at 10 and 
20  min in the groups receiving Cys than in the group 
receiving ART alone, suggesting longer persistence of 
DHA in animals receiving Cys. These results suggest that 
in addition to the direct potentiation of ART anti-plas-
modial activity (Figs. 2, 3, 4), Cys treatment in vivo may 
favorably modify the pharmacokinetics and metabolism 
of artemisinin to its active form DHA (enhanced trans-
formation, and increase in plasma AUC), further increas-
ing its anti-parasitic activity.
The mechanistic basis of the observed in  vitro and 
in vivo eﬀects remain to be fully elucidated but may addi-
tionally involve the anti-oxidant properties of the thiol 
group of Cys. Indeed, anti-oxidants have been proposed 
to improve malaria outcomes, but this has remained 
controversial. While some studies show that anti-oxi-
dants may improve recovery from Plasmodium-induced 
oxidative stress [35, 36], other studies have not seen these 
eﬀects, in fact arguing the opposite view as artemisinin 
plasmodial toxicity depends on in situ generation of free 
radicals which could be blunted by Cys [37, 38]. Because 
several of these studies used N-Acetyl Cysteine as an 
anti-oxidant, Cys and NAC were compared for potentia-
tion of artemisinin in our experimental conditions. These 
studies showed that the Cys eﬀect is speciﬁc, and that 
NAC has no activity when used in the same assay condi-
tions (Fig. 4). This is supported by the ﬁndings that Cys 
anti-plasmodial activity is speciﬁc and not seen for other 
thiols such as dimercaptosuccinic acid (DMSA) [24].
Cys is a small aminothiol produced by the pantethei-
nase reaction which has very low toxicity, and various 
formulations of Cys have been approved for clinical use 
in the life-long management of nephropathic cystino-
sis, a rare pathology caused by mutations in the cysteine 
transporter [25]. For example, starting in early childhood, 
cysteamine bitartrate is given a following dose escalation 
schedule to reach a ﬁnal dosing of ~2 g per day (divided 
into 4 daily doses) for a ~45–50 kg child. Continuous use 
of Cys at these doses over several years shows low tox-
icity in humans [39]. The pharmacokinetic proﬁle of a 
single dose of 1.5  g of cysteamine bitartrate in humans 
(Cmax = 80 μM; AUC = 2845.1 min μM) is similar to sin-
gle subcutaneous (sc) injection of 50  mg/kg cysteamine 
hydrochloride in mice [26]. Here, Cys (cysteamine hydro-
chloride) can potentiate the anti-plasmodial potency 
of the artemisinin derivatives ART, ARTE and ARTM 
in vivo over a wide dose range, and at doses (40–60 mg/
kg) that are well within the range of those used to treat 
human cystinosis. In addition, studies in  vitro show 
that 1  h exposure to doses of Cys as low as 10–25  μM 
are suﬃcient to signiﬁcantly potentiate anti-plasmodial 
activity of ART against both P. chabaudi and P. berghei. 
These Cys concentrations are well within the range of the 
Cmax values (20–150  μM) reached by a single oral dose 
of cysteamine bitartrate used in humans [39–42]. The 
observations that (a) Cys is well tolerated and already in 
clinical use for chronic cystinosis, (b) it has anti-plasmo-
dial activity of its own, (c) it can potentiate the eﬀect of 
artemisinin derivatives currently in use, and at concen-
trations within the range of those currently in use for cys-
tinosis treatment together strongly suggest that Cys has 
essential features of a new partner for artemisinin deriva-
tives in current ACT.
Artemisinin included in ACT is currently the most 
important drug for the clinical treatment of malaria. 
Resistance to artemisinin in the malaria parasites would 
be a major threat to global health. Unfortunately, several 
reports have documented the recent emergence of arte-
misinin resistance, in particular at the Thai-Cambodia 
border area [12–16]. This has prompted the search for 
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new therapeutic intervention, and new drug candidates 
with anti-plasmodial activity [43–48]. Results from the 
current study suggest that modiﬁcation of current ACT 
by incorporation of Cys could represent a signiﬁcant 
alternative for management of artemisinin-resistant Plas-
modium malaria parasites.
Conclusions
This report shows that Cys in combination with arte-
misinin can signiﬁcantly improve the outcome of both 
blood-stage and cerebral malaria in mouse models of 
these two infections. In addition, the potentiating eﬀect 
of Cys is broad and improves activity of several arte-
misinin derivatives used for clinical treatment of malaria 
in humans. In particular, the eﬀect of Cys in the cerebral 
malaria model, where artemisinin is used as a single 
agent in humans, strongly suggests that its inclusion in 
management of these patients may signiﬁcantly improve 
outcome. Cys potentiation might help overcome emerg-
ing artemisinin resistance in Plasmodium parasites and 
may widen its therapeutic activity. Taken together, these 
studies are a necessary pre-requisite to the clinical evalu-
ation of Cys/ART combinations in humans.
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